4.5 Letter

HLA-haploidentical donor transplants with post-transplant cyclophosphamide in children with primary immune deficiency disorders

Related references

Note: Only part of the references are listed.
Article Biophysics

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases

Ehud Even-Or et al.

Summary: Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PT-Cy) is a feasible option for pediatric patients with nonmalignant diseases lacking a matched donor. Engraftment failure is a concern, but salvage options including a second PT-Cy transplant or CD34+ selected graft may be successful. Graft-versus-host disease was not observed in any of the patients, with early posttransplant infectious complications leading to mortality in some cases.

BONE MARROW TRANSPLANTATION (2021)

Review Biochemistry & Molecular Biology

Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease

Haitham Abdelhakim et al.

BIOMEDICINES (2017)

Article Biophysics

Stem cell transplantation for primary immunodeficiencies

F. Porta et al.

BONE MARROW TRANSPLANTATION (2008)